NAOX Link is an FDA-cleared in-ear EEG device that patients self-apply at home to capture long-duration brain recordings comparable to hospital-grade monitoring.
Photo source:
Naox
Epileptic seizures happen at night.
Neurological symptoms appear during sleep, during stress, during the ordinary
moments of a day that a hospital visit cannot replicate. Yet the gold standard
for capturing them, a clinical EEG, requires a patient to travel to a hospital,
sit through a technician applying paste and electrodes across their scalp, and
then attempt to sleep or relax naturally in a clinical environment while being
monitored. The result is often a recording that captures nothing useful, because
the symptom that brought the patient in simply does not happen on demand in a
clinical room.
NAOX built the NAOX Link to solve exactly that
gap. The device is a unique in-ear EEG screening device cleared by the FDA for
medical use, designed to be handed directly to a patient so they can apply it
themselves at home, as intuitively as plugging in earbuds to listen to music.
Once in, they can select a quiet moment to record or capture an entire night
on a single charge, returning the kind of real-world brain data that a clinical
visit almost never produces.
The most important question about an in-ear EEG
is whether it actually works, and NAOX has answered that with peer-reviewed
science rather than marketing claims. Synchronous dual recordings conducted in
hospital settings, where NAOX Link recorded simultaneously alongside
gold-standard scalp EEG, confirmed that in-ear EEG signals are comparable to a
low temporal derivation from standard scalp electrodes. Independent published
research validated that EEG recorded with NAOX is comparable to gold-standard EEG
across various conditions, including wakefulness and sleep.
What the in-ear position captures are the same
EEG rhythms that clinicians use to characterize brain states: slow waves,
theta, alpha, and sleep spindles, each corresponding to specific brain states
including sleep stages N1 through N3, relaxation, and focused attention. In
addition, the device successfully detected an epileptic seizure in a real-world
scenario during clinical testing, confirming that the signal quality is
clinically meaningful rather than just technically similar on paper.
Furthermore, because the earbuds are designed to be comfortable and stay in
place even for side-sleepers, patients can wear them through an entire night
without the discomfort that causes clinical recordings to fail.
The practical impact of a self-applied home EEG
device reaches both sides of the clinical relationship. For physicians, the
NAOX Link directly addresses the two most common barriers to useful EEG data:
long waiting lists caused by staffing shortages, and the fundamental problem
that symptoms happen at home rather than in a clinical setting. When a
physician suspects nocturnal events, patient reluctance to undergo hospital
monitoring or the complexity of traditional home setups often leaves them
without the data needed to diagnose or rule out a condition. Handing a patient
the NAOX Link changes that dynamic entirely, giving the physician access to
long-duration, real-world brain recordings without any clinic time or technical
setup.
For patients, particularly those living with
epilepsy or suspected neurological conditions, the device removes the anxiety
of clinical monitoring and replaces it with something genuinely manageable. One
neurologist described the project as marking a turning point in the history of
EEG by providing concrete solutions for patients and new opportunities for
studying brain activity. A patient with epilepsy described it as the
groundbreaking innovation that people with epilepsy have been waiting for
years. The NAOX In-Ear EEG platform is intended for prescription use in the
home, healthcare facility, or clinical research environment, for adult and
pediatric patients aged six and above, with all medical interpretation
performed under the direction of a licensed medical professional.
Please subscribe to have unlimited access to our innovations.